Galapagos NV

595 articles about Galapagos NV

• Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

  11/6/2023

  Landmark Bio announced that it has signed a multi-year strategic manufacturing agreement with Galapagos NV (Euronext & NASDAQ: GLPG), an innovative biotech company with operations in Europe and the U.S.

• Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

  11/2/2023

  Galapagos NV announced its financial results for the first nine months of 2023, a year-to-date business update and its outlook for the remainder of 2023.

• Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

  10/30/2023

  Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 positions in 14 European countries.

• Galapagos appoints Simon Sturge to its Board of Directors

  9/19/2023

  Galapagos NV announced that during its meeting of 19 September2 023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation.

• Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  

  8/28/2023

  The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.

• Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

  6/15/2023

  Galapagos NV announced the appointment of Thad Huston as Chief Financial Officer and Chief Operating Officer as per 1 July 2023.

• Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

  6/12/2023

  Galapagos NV announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director.

• Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress

  6/5/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and will present previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany.

• Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis

  5/23/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.

• Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023

  5/22/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world evidence (RWE) studies at the European League Against Rheumatism (EULAR) annual congress taking place from 31 May to 3 June 2023 in Milan.

• Galapagos creates new subscription right plans - May 05, 2023

  5/5/2023

  Galapagos NV announced that its Board of Directors created 1,975,000subscription rights under new subscription rightplans for the benefit of certain members ofthe personnelof the company and its subsidiaries.

• Galapagos announces first quarter 2023 financial results

  5/4/2023

  Galapagos NV announced its first quarter 2023 financial results, a year-to-date business update and its outlook for the remainder of 2023.

• Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer

  5/2/2023

  Galapagos NV announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer.

• Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis

  4/26/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.

• Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting

  4/25/2023

  Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.

• Galapagos and NovAliX enter into an integrated drug discovery collaboration

  3/30/2023

  Galapagos NV (Euronext & NASDAQ: GLPG)and NovAliX today announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization.

• Galapagos publishes 2022 annual report and announces Annual Shareholders’ Meeting

  3/23/2023

  Galapagos NV publishes its annual report for the financial year 2022 and announces its Annual Shareholders’ Meeting,to be held on Tuesday 25 April 2023, at 2:00 p.m., at the registered office of the company.

• Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

  2/27/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) will present new data at the European Crohn’s and Colitis Organization (ECCO) annual congress taking place from 1-4 March 2023.

• Galapagos announces full year 2022 results and outlook for 2023

  2/23/2023

  Galapagos NV reports 2022 results, supported by strong adoption of Jyseleca® across Europe, and provides outlook for 2023.

• Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

  2/9/2023

  Galapagos NV (Euronext & NASDAQ: GLPG) today presented encouraging data at the European Society for Blood and Marrow Transplantation(EBMT)-European Hematology Association (EHA)5thEuropean CAR T-cell Meeting in Rotterdam.